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Abstract: Ribosomal RNA (rRNA) is extensively edited through base methylation and acetylation,
2′-O-ribose methylation and uridine isomerization. In human rRNA, 95 uridines are predicted to by
modified to pseudouridine by ribonucleoprotein complexes sharing four core proteins and differing for
a RNA sequence guiding the complex to specific residues to be modified. Most pseudouridylation sites
are placed within functionally important ribosomal domains and can influence ribosomal functional
features. Information obtained so far only partially explained the degree of regulation and the
consequences of pseudouridylation on ribosomal structure and function in different physiological and
pathological conditions. This short review focuses on the available evidence in this topic, highlighting
open questions in the field and perspectives that the development of emerging techniques is offering.
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1. RNA Pseudouridylation and Its Roles in Ribosome Biogenesis
Pseudouridine (Ψ) is the 5-ribosyl isomer of uridine (Figure 1). It derives from the uracil base
rotation of 180◦, which makes the uracil attached to the 1′ carbon (C1´) of the ribose via a carbon-carbon
instead of a nitrogen-carbon glycosidic bond (see [1,2] for a broader review). Pseudouridine (Ψ) is the
most prevalent within more than 100 different modified nucleosides found in RNA, with about 9500 Ψ
residues identified in mammals and yeast and deposited in the RMBase database [3]. Pseudouridine
(Ψ) is found in all species and in many classes of RNA, including ribosomal RNA (rRNA), transfer
RNA (tRNA), mitochondrial tRNAs (Mt-tRNAs), small Cajal Body-specific RNAs (scaRNAs), small
nucleolar RNAs (snoRNAs), microRNAs (miRNAs), long intergenic non-coding RNAs (lincRNAs),
messenger RNAs (mRNAs), and other miscellaneous RNAs (misc_RNAs) [4]. Uridine isomerization to
Ψ is carried out by either RNA-driven enzymatic complexes or stand-alone enzymes, depending on the
class of the RNA harboring the target residue. In rRNA, Ψs are generated by RNA-guided enzymatic
complexes, and they account for about the 1.4% of all bases, with a total of 95 predicted Ψs in human
28S, 18S, 5.8S, and 5S rRNAs [5–7]. In bacteria and yeast rRNAs, the number of Ψs is significantly
lower (36 in E. coli, 46 in S. cerevisiae [8]), mirroring the complexity level of these organisms.
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biochemical  and  biophysical  properties  distinct  from  those  of  uridine  and  all  other  known 
nucleotides.  In  particular,  the  presence  of  Ψ  is  able  to  provide:  (i)  greater  rigidity  to  the 
phosphodiester backbone of the RNA; (ii) stabilization of Ψ‐A base pairs (compared to that of U‐A 
base  pairs)  through  some  effects  on  base  stacking  and water  coordination,  thus  affecting  RNA 
structure, spatial conformation and, ultimately, its functional properties; and (iii) increased thermal 
stability (reviewed in [9]). 
The  site‐specific modification  of  target  uridines  in  rRNA,  as  for  other modification  types 
occurring  in  this class of RNA, represents an extremely  important passage of ribosome synthesis. 
Many aspects of uridine modification process are now quite clear, including the players involved, the 






considered  important  for ribosome production  to occur, since  this process  is characterized by  the 
presence of multiple control steps, which, in the end, ensure the production of competent ribosomes.   
Ribosomal  RNA  is  synthesized  by  two  different  RNA  polymerases.  While  5S  rRNA  is 
transcribed by RNA PolIII in the nucleoplasm, mature 5.8S, 18S, and 28S rRNAs are derived from a 
unique precursor,  termed 47S, also harboring  two external  transcribed spacers  (5′ and 3′ external 
transcribed  spacer  (ETS))  and  two  internal  transcribed  spacers  (ITS1  and  2)  transcribed  in  the 
nucleolus  by  RNA  PolI.  ETS  and  ITS  sequences  are  sequentially  removed  by  exo‐  and  endo‐






box).  Structurally H/ACA  snoRNAs  are  characterized by  the presence of  a double hairpin,  each 
harboring a pseudouridylation pocket, which  is specific  to a particular  target sequence, based on 
sequence‐specific base pairing. The interaction between the guide snoRNA and the substrate guides 
the  enzymatic  complex on  the  target uridine. A  further  stabilization occurs  thanks  to  additional 
interactions of  the  substrate RNA with protein  component of  small nucleolar  ribonucleoproteins 
(snoRNPs) and in particular with DKC1, which carries out the isomerization of the target uridine (see 
[5,12] for a comprehensive review). 
Most  interactions between pre‐rRNA  and pseudouridylation RNP  complexes may occur  co‐
transcriptionally; indeed in yeast it has been shown that pre‐ rRNA transcripts are first completed 
and  modified  before  further  processing,  probably  because  modifications  are  required  for  the 
acquisition of structural conformations necessary for the occurrence of later processing events [13]. 
On this regard, it is not definitively clear if each of the predicted snoRNA guided associations also 
Figure 1. Structure for ulae of uridine and pseudouridine.
The presence of an extra hydrogen bond donor at its non-Watson-Crick edge endows Ψ with
biochemical and biophysical properties distinct from those of uridine and all other known nucleotides.
In particular, the presence of Ψ is able to provide: (i) greater rigidity to the phosphodiester backbone
of the RNA; (ii) stabilization of Ψ-A base pairs (compared to that of U-A base pairs) through some
effects on base stacking and water coordination, thus affecting RNA structure, spatial conformation
and, ultimately, its functional properties; and (iii) increased thermal stability (reviewed in [9]).
The site-specific modification of target uridines in rRNA, as for other modification types occurring
in this class of RNA, represents an extremely important passage of ribosome synthesis. Many aspects
of uridine modification process are now quite clear, including the players involved, the timing
and the cellular localization of the processes, and the position on rRNAs in the three-dimensional
structure of the ribosome (even though all of this information might n t be availabl for e ch single
modification) [10]. Still, to understand the function (or functions) of many f these Ψs r mains a
demanding challe ge for inv stigators in the field.
Pseudouridylation, together with other r ifications, is only one aspect of the process of
preparation of rRNAs for riboso e biogenesis. As discussed later on, some of these modifications
are considered important for ribosome production to occur, since this process is characterized by the
presence of multiple control steps, which, in the end, ensure the production of competent ribosomes.
Ribosomal RNA is synthesized by two different RNA polymerases. While 5S rRNA is transcribed
by RNA PolIII in the nucleoplasm, mature 5.8S, 18S, and 28S rRNAs are derived from a unique
precursor, termed 47S, also harboring two external transcribed spacers (5′ and 3′ external transcribed
spacer (ETS)) and two internal transcribed spacers (ITS1 and 2) transcribed in the nucleolus by
RNA PolI. ETS and ITS sequences are sequentially removed by exo- and endo-nucleolytic cleavages,
in coordinated series of processing events that may present variations depending on cellular type
or status (for a broader review of the topic please refer to [11]). In rRNA, pseudouridylation is
carried out by ribonucleoprotein (RNP) complexes called H/ACA box RNPs, each consisting of one
H/ACA s oRNA and four core proteins, amely GAR1, NHP2, NOP10 and dyskerin (DKC1). H/ACA
snoRNAs contain a conserv d ANANNA sequence called “hinge box” (indicate with H) and a
sequence of three nucleotide (ACA) present at the r 3′ end (called ACA box). Structurally H/ACA
snoRNAs are characterized by the presence of a double hairpin, each harboring a pseudouridylation
pocket, which is specific to a particular target sequence, based on sequence-specific base pairing.
The interaction between the guide snoRNA and the substrate guides the enzymatic complex on the
target uridine. A further stabilization occurs thanks to additional interactions of the substrate RNA
with protein component of small nucleolar ribonucleoproteins (snoRNPs) and in particular with DKC1,
which carries out the isomerization of the target uridine (see [5,12] for a comprehensive review).
Most interactions between pre-rRNA and pseudouridylation RNP complexes may occur
co-transcriptionally; indeed in yeast it has been shown that pre- rRNA transcripts are first completed
and modified before further processing, probably because modifications are required for the acquisition
of structural conformations necessary for the occurrence of later processing events [13]. On this regard,
it is not definitively clear if each of the predicted snoRNA guided associations also require the
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modification to occur or if instead, in some cases, the molecular interaction is sufficient to allow for
the processing.
2. Role of Pseudouridine Formation on Ribosome Function
Considering the three dimensional (3D) structure of the mature ribosome, it is also interesting
to notice that many pseudouridylation sites are placed in (or very near to) functionally important
ribosomal sites, such as tRNA and mRNA binding sites [14]. This suggests that pseudouridylation
at these specific sites could impact on ribosomal function. Interestingly, while pseudouridylation is
required for ribosome biogenesis and ribosomal function in eukaryotes, it has been possible to generate
strains of bacteria lacking completely rRNA pseudouridylation and displaying only minor defects of
ribosome biogenesis and ribosomal function [15]. These findings suggest a differential requirement
for Ψ modifications for prokaryotic and eukaryotic cells. Recent studies aimed to study the role of
specific Ψs in functionally important sites in yeast ribosomes, by deleting snoRNA sequences guiding
these specific modifications. By this approach, it. was shown that depleting yeast cells of snoRNAs
guiding modifications in the peptidyl transferase center alters ribosome function particularly when a
conserved Ψ modification in the A site of tRNA binding is lost [16]. In addition, loss of Ψ residues
at the intersubunit bridge, with particular reference to the helix 69 in the large ribosomal subunit,
may induce a number of structural and functional effects including reduced amino acid incorporation,
increased stop codon readthrough, and increased sensitivity to antibiotics targeting the ribosome [17].
Moreover, loss of modification in the decoding center has complex, position-dependent, outcomes that
span from no apparent effects (for single modification loss) to reduced amino acid incorporation and
delayed cell growth, to strong ribosome biogenesis defects [18].
On the other hand, a greatly lower amount of data is available in human/mammalian systems,
and the information we have is mostly linked to human disorders such as inherited disorders involving
genes encoding for components of the pseudouridylation complex and cancer and is therefore
discussed in the following section.
3. rRNA Pseudouridylation and Disease
The first evidence linking rRNA pseudouridylation and human disease dates back to 20 years
ago, when mutations of the DKC1 gene encoding the pseudouridine synthase dyskerin were
identified in X-linked dyskeratosis congenita (X-DC) patients [19]. X-DC is a multisystemic syndrome
characterized by failure of proliferating tissue (skin, mucosae and bone marrow) and increased cancer
susceptibility [20]. As reported above dyskerin is part of the pseudouridylation complex mediating
pseudouridylation in rRNA and therefore X-DC has been defined as a ribosomopathy: a disease
due to ribosome malfunction. Soon afterwards dyskerin was found to be part of the telomerase
complex through direct interaction with telomerase RNA component (TERC) [21] and the pathogenesis
of X-DC was therefore ascribed also to telomere attrition [22]. To better dissect this issue, studies
in DKC1 hypomorphic mouse models were conducted. These showed that a recapitulation of the
clinical defects observed in X-DC patients, including cancer susceptibility and bone marrow failure,
takes place together with a reduction of the global levels of Ψs in rRNA and with an impairment
in the translation of a group of cellular mRNAs [23,24]. These mRNAs contain specific sequence
elements termed internal ribosome entry site (IRES) [23]. IRES elements are highly structured
nucleotide sequences, originally reported in viral mRNAs but present also in a limited number
of eukaryotic cellular mRNAs [25], that can mediate translation initiation independently of the
canonical cap-dependent mechanism. The experimentally verified translational targets found in
cells expressing low dyskerin levels include Bcl-xL and XIAP (X-linked inhibitor of apoptosis protein)
mRNAs, encoding for antiapoptotic factors [23], and p27(Kip1) and p53 [23,26,27] mRNAs, encoding
for tumor suppressors. In addition, the translation of other IRES-containing mRNAs (such as vascular
endothelial growth factor -VEGF and heat shock protein 70-HSP70 mRNAs [28]) increase after
DKC1 depletion, indicating a complex remodulation of translational regulation in these conditions.
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Likewise, the translational fidelity is also strongly lowered in cells after partial DKC1 depletion [29].
Importantly, experiments performed by means of a reconstituted cell-free in vitro translation system
ascribed all the observed translational changes to the intrinsic ribosomal alterations induced by
reduced global pseudouridylation of rRNA [30]. These observations, highlighting the effects of
rRNA pseudouridylation reduction on translational control, may help explaining both the defect in
proliferating tissues and the cancer susceptibility typical of X-DC [31]. Interestingly, mutations of the
DKC1 gene have been also reported in familial interstitial pneumonia [32].
In addition to these inherited disorders, a subset of human cancers arising in the general
population display reduced dyskerin expression and functions and low rRNA pseudouridylation
suggesting that the observed translational defects may also contribute to the neoplastic phenotype
in a fraction of sporadic tumors [31,33]. On this concern, a highly variable dyskerin expression has
been observed in a variety of human tumor types, including breast, lung, prostate, colon, head and
neck, and hepatocellular carcinomas [31,34–36]. In general, low dyskerin expression is associated with
a favorable clinical behavior [35–37].
To appreciate the contribution of altered rRNA pseudouridylation in inherited disorders and in
tumorigenesis, the expression of components of H/ACA snoRNP complexes in different pathological
conditions should be considered beyond altered DKC1 expression. Autosomal forms of Dyskeratosis
Congenita can derive from mutations of NOLA2 or NOLA3 encoding for NHP2 and NOP10,
respectively [38,39]. Similarly to dyskerin, the expression of these genes is also found altered in
human neoplasms and is associated with disease aggressiveness [40]. As for DKC1, the products of
NOLA2 and NOLA3 genes are both involved in telomerase function and in RNA pseudouridylation.
In addition, the expression of snoRNAs has been found to be deregulated in a series of human
disorders including cancer, neurodegenerative, and viral diseases and also in response to stress and
treatment with specific drugs [41]. The expression of different H/ACA snoRNAs is deregulated in a
series of human neoplasms of different origins (see McMahon et al. for review [42]). On this regard,
it is important to consider that snoRNA expression is under the control of tumor suppressive and
oncogenic signaling pathways [43,44], which can therefore alter rRNA modification levels during the
cellular transformation process. Of note, the majority of these studies analyzed snoRNAs expression
from library preparations specific for small RNAs, implying the loss of a large fraction of snoRNA
of middle to large size. The frequency of these alterations could be therefore largely underestimated.
In addition, recent genome wide studies identified frequent alterations in snoRNA genes in human
cancer, including in particular gene amplification and homozygous deletion [45–47]. An implication of
these findings is that in particular pathological contexts rRNA pseudouridylation can be altered by the
relative lack or abundance of the activity of factors mediating the modification.
Very recently, high-resolution structural cryogenic electron microscopy (cryo-EM) studies
demonstrated that, in human ribosomes, rRNA modifications are distributed into a wide ribosome
portion including important functional domains. There is evidence that such modifications are altered
in cancer cells [48]. Such studies are currently in a pioneering stage and it can be expected that provided
that the required methodology will become available a large amount of information regarding rRNA
pseudouridine modification in cancer could be obtained, shedding light on its relevance in ribosomal
function and cancer development.
Figure 2 outlines how defects in the H/ACA RNP pseudouridylation complex may be involved
in different human disorders.
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implying  that  not  all  rRNAs  are  similarly modified.  It  is worthwhile  to  underline  that  such  an 
approach can be very informative for 2′‐O‐methylation, which is by itself exploitable for direct and 
confident  identification by high‐throughput sequencing  techniques. Unfortunately,  the equivalent 
high‐throughput  approaches  for  Ψ  detection  (Pseudo‐Seq,  Ψ‐Seq,  PSI‐Seq  [53–55])  should  be 
interpreted  with  caution,  since  they  are  all  based  on  the  use  of  N‐cyclohexyl‐N’‐β‐(4‐
methylmorpholinium)ethylcarbodiimide (CMC), which has been reported to bind with  inconstant 
efficiency, thus possibly introducing a bias for quantitative interpretation of results [56]. The proof of 
the  existence  of  diversified  ribosomes  pools  is,  in  line  of  principle,  a  very  strong  indication  of 




the  study of  ribosome diversity with  the needed  sensitivity.  Initial  studies  conducted  to  identify 
pseudouridylation sites on rRNA were based on the use of CMC in conjunction with Sanger‐based 
Figure 2. Schematic representation of the Box H/ACA riboucleoprotein (RNP) pseudouridylation
complex, with particular reference to the diseases associated to alterations in the expression of
each component.
4. Are Ribosome All Modified at the Sa
Ribosomal RNA modifications are thought to be one of the main sources of ribosomes
heterogeneity, either in physiological or in pathological conditions. Intriguingly, different studies
have recently clarified that subpopulations of diversely modified mature ribosomes may co-exist
in single cells ([49–51]. In these studies next-generation sequencing-based RiboMethSeq [52]
mapping of 2′-O-methylated rRNA residues highlighted the existence of sub-stoichiometrically
modified sites, implying that not all rRNAs are similarly modified. It is worthwhile to underline
that such an approach can be very informative for 2′-O-methylation, which is by itself
exploitable for direct and confident identification by high-throughput sequencing techniques.
Unfortunately, the equivalent high-throughput approaches for Ψ detection (Pseudo-Seq, Ψ-Seq,
PSI-Seq [53–55]) should be interpreted with caution, since they are all based on the use of
N-cyclohexyl-N’-β-(4-methylmorpholinium)ethylcarbodiimide (CMC), which has been reported to
bind with i onstant efficiency, thus possibly introducing a bias for quantitative interpretation
of results [56]. The proof of the existenc of diversified ribosomes pools s, in line of principle,
a very strong indication of rib some functional specialization. Indeed, functional assays rformed
in different cellular b ckgr unds have already proven that pseudouridylation defects may alter
translational c mpetence [28–30,33], and we have shown that intrinsic ribosomal functional efects
arise as a consequence of rRNA pseudouridylation down-regulation [30]. However, technical
limitations have so far impeded the study of ribosome diversity with the needed sensitivity. Initial
studies conducted to identify pseudouridylation sites on rRNA were based on the use of CMC
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in conjunction with Sanger-based sequencing techniques [57]. More recently, in the era of next
generation sequencing (NGS), several different approaches have been developed to identify and
quantify Ψs at specific positions in RNAs [53–55,58]. Albeit these techniques are highly sensitive,
in addition to what above reported, they have been applied to the research of pseudouridylated
sites in whole cellular RNAs and therefore did not fully address the issue of the abundance of
specific Ψ residues on mature ribosomes. Moreover, the high amount of rRNA may interfere in the
achievement of an adequate coverage by RNAseq in order to obtain a quantitative evaluation of the
number of modified sites. In addition to sequencing techniques, cryo-EM was, as mentioned above,
recently exploited to localize and visualize rRNA modifications directly in mature, 80S ribosomes
from HeLa cells [48]. Thanks to an extremely high resolution (up to 2.5 Å), it was possible to address
the 3D localization of many modified residues in rRNAs, even though only a small fraction of the
predicted modifications was identified on mature ribosomes due to technical limitations. For instance,
only 21 Ψs were confirmed by this technique out of the expected 95. The 95 predicted Ψs have
never been identified before on mature ribosomes; instead, they were either predicted based on
sequence-specificity of guide snoRNAs or mapped by sequencing approaches on total cellular rRNAs,
and therefore could not faithfully mirror the modification status of each single residue in mature
ribosomes. (see https://www-snorna.biotoul.fr/index.php, [8,59]). These considerations also open up
new questions about the inducible nature of rRNA modifications in general, and of pseudouridylation
in particular, paralleling what has been proposed for 2′-O-methylation, that is the presence of a core of
conserved modifications sites, associated to a peripheral shell of “vulnerable” sites being modified in a
regulated manner in different settings [50]. Indeed, it is possible that only a fraction of the predicted
Ψs are necessary for a correct rRNA maturation/assembly with ribosomal proteins, and the rest may
be added only in specific cellular contexts. In addition, it is possible that rRNA modifications in
human ribosomes may differ between cell types, or within the same cell type, between physiology
and pathology. Studies addressing these issues are probably slowed down by the lack of appropriate
technical approaches, allowing for physical particle sorting and analysis needed for the identification
of structurally/functionally distinguishable ribosomal (sub)populations.
From a functional standpoint, the possibility to assay the activity of diversely modified ribosomes
might be even more challenging. We have set up a cell free translation system suitable for testing, in a
controlled setting, different aspects of the translational activity of ribosomes stringently purified from
cultured cells [60]. Even though this tool is extremely helpful to investigate the functional outcomes
of structural alterations in widely represented ribosomal populations within cells, it does not allow
evaluating the translational contribution of ribosomal sub-populations that are less abundant. To this
end, innovative approaches are needed, aiming to separate ribosomal subpopulations on a structural
basis prior to their functional testing.
5. Concluding Remarks
The importance of rRNA pseudouridylation and of its regulation (as for other modifications)
has been largely underexplored for many reasons. The impact of the presence/absence of a single
modification or combinations of a limited number of modifications has been explored only in yeast,
and the scientific community currently has limited information on how this could be important
in regulating mammalian ribosome function, protein synthesis, and gene expression in different
physiological states and in many human disorders. For instance, it is known that under mammalian
target of rapamycin (mTOR) activation, specific residues can be modified upon up-regulation of single
H/ACA guide RNA [61], and something similar could happen under different stimuli.
In addition, the timing of specific modifications may be under some kind of control in mature
ribosomes, since many sites lie on exposed domains potentially reachable by the pseudouridylation
complexes, similarly to what has been reported for mRNA [62].
Moreover, at the specific site level, the regulation of the modification may depend on the
availability of guide RNAs or on the accessibility/masking of the substrate by means of additional
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factors. To clarify these points may represent an important area of research for cellular and molecular
biologists, with the potential to provide unconsidered keys for interpreting gene expression regulation
in many pathological processes. Recent results suggest that it may not be rigorous enough to
assume the presence or the absence of a single modification when assaying it using only one kind of
technical method.
To obtain a complete picture, therefore, will require the development of multiple additional
model systems and further technical approaches both at the structural and functional level and the
development of a solid awareness regarding ribosome-mediated gene expression control, a scientific
challenge we are currently only begin to tackle.
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